Details for New Drug Application (NDA): 019385
✉ Email this page to a colleague
The generic ingredient in PERMAX is pergolide mesylate. There are four drug master file entries for this compound. Additional details are available on the pergolide mesylate profile page.
Summary for 019385
Tradename: | PERMAX |
Applicant: | Valeant Pharm Intl |
Ingredient: | pergolide mesylate |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 019385
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 0.05MG BASE | ||||
Approval Date: | Dec 30, 1988 | TE: | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 0.25MG BASE | ||||
Approval Date: | Dec 30, 1988 | TE: | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 1MG BASE | ||||
Approval Date: | Dec 30, 1988 | TE: | RLD: | No |
Expired US Patents for NDA 019385
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Valeant Pharm Intl | PERMAX | pergolide mesylate | TABLET;ORAL | 019385-003 | Dec 30, 1988 | ⤷ Sign Up | ⤷ Sign Up |
Valeant Pharm Intl | PERMAX | pergolide mesylate | TABLET;ORAL | 019385-001 | Dec 30, 1988 | ⤷ Sign Up | ⤷ Sign Up |
Valeant Pharm Intl | PERMAX | pergolide mesylate | TABLET;ORAL | 019385-001 | Dec 30, 1988 | ⤷ Sign Up | ⤷ Sign Up |
Valeant Pharm Intl | PERMAX | pergolide mesylate | TABLET;ORAL | 019385-002 | Dec 30, 1988 | ⤷ Sign Up | ⤷ Sign Up |
Valeant Pharm Intl | PERMAX | pergolide mesylate | TABLET;ORAL | 019385-002 | Dec 30, 1988 | ⤷ Sign Up | ⤷ Sign Up |
Valeant Pharm Intl | PERMAX | pergolide mesylate | TABLET;ORAL | 019385-002 | Dec 30, 1988 | ⤷ Sign Up | ⤷ Sign Up |
Valeant Pharm Intl | PERMAX | pergolide mesylate | TABLET;ORAL | 019385-003 | Dec 30, 1988 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription